Beam Therapeutics Files Q1 2025 10-Q
Ticker: BEAM · Form: 10-Q · Filed: May 6, 2025
Sentiment: neutral
Topics: 10-Q, financials, liabilities, licensing
TL;DR
Beam Therapeutics Q1 2025 10-Q filed. Financials look stable, focus on liabilities and fair value.
AI Summary
Beam Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 26 Landsdowne Street, Cambridge, MA, reported on its financial status. Key financial data points include fair value measurements and liabilities related to product agreements and licenses.
Why It Matters
This filing provides investors with an update on Beam Therapeutics' financial health and operational status for the first quarter of 2025, including details on liabilities and fair value measurements.
Risk Assessment
Risk Level: medium — The filing contains financial data and disclosures that require careful analysis to assess the company's risk profile.
Key Numbers
- 2025-03-31 — Period End Date (Reporting period for the 10-Q)
- 2024-12-31 — Previous Year End Date (Used for comparative financial reporting)
- 2025-01-01 — Sales Agreement Start Date (Beginning of the period for Jeffries LLC sales agreement)
Key Players & Entities
- Beam Therapeutics Inc. (company) — Filer of the 10-Q
- 26 LANDSDOWNE STREET (location) — Business and mailing address
- CAMBRIDGE, MA (location) — City and State of business address
- 02139 (location) — ZIP code of business address
- 20250331 (date) — Period of report
- 20250506 (date) — Filing date
- Jeffries Llc (company) — Mentioned in relation to a sales agreement
FAQ
What is the total revenue reported for the quarter ending March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ending March 31, 2025.
What were the total operating expenses for the period?
The provided text does not detail the total operating expenses for the period.
What is the company's cash and cash equivalents balance as of March 31, 2025?
Specific figures for cash and cash equivalents are not present in the provided excerpt.
What are the key liabilities disclosed related to product agreements?
The filing mentions 'ContingentConsiderationOfProductLiabilitiesMember' and 'ContingentConsiderationLiabilitiesMember', indicating potential future obligations related to products.
What is the nature of the 'BroadLicenseAgreementMember' mentioned?
The filing references a 'BroadLicenseAgreementMember' and associated 'SuccessPaymentLiabilitiesMember', suggesting liabilities tied to licensing agreements.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Beam Therapeutics Inc. (BEAM).